A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (Iressa) Versus Intravenous Docetaxel (Taxotere) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA)
Latest Information Update: 12 Jun 2012
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ISTANA
- Sponsors AstraZeneca
- 09 Feb 2010 Results published in Clinical cancer research: an official journal of the American Association for Cancer Research.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2008 Status changed from completed to active, no longer recruiting.